الفهرس 
Feasibility of concurrent paclitaxel and radiotherapy after adjuvant doxorubicin and cyclophosphamide for node-positive breast cancer
LIST OF CONTENTSOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
Bakground: Concurrent chemo-radiotherapy in breast cancer (BC) may yield better local control with minimal toxicity in node positive patients. The feasibility of paclitaxel with radiotherapy was asses for tolerability, cosmetic outcome as well as local control. Methods: All female BC with stage II-III were included in the study. Adjuvant chemotherapy was 4 cycles AC (doxorubicin 60mg/m2+ cyclophosphamide 600mg/m2) followed by 4 cycles of paclitaxel 60mg/m2 weekly for 12 weeks concurrent with 3D CRT in a dose of 45Gy/20ttt/4wks to the whole breast and supraclavicular nodal region. Boost of 10Gy/5ttt was given to the tumor bed in conservative cases. Evaluation of lung function was done by carbon monoxide diffusion. Radiotherapy toxicity and breast cosmesis were assessed by the RTOG and harvard criteria respectively. Results: There were 40 patients, 60% underwent modified radical mastectomy and 60% had conservative surgery. The mean age was 50 years (31-70). With 38months follow up, the overall survival was 92% with no local relapse or radiation pneumonitis. There is no significant change in carbon monoxide diffusion after radiotherapy (p:0.55). There was 15% delay in radiotherapy mainly due to acute GIII toxicity followed equally by mucositis, tender erythema and wound gap. Volume of irradiated breast tissue was correlated with acute cosmesis and grade III skin toxicity only in one patient